NG2 and DLL3 CAR-T Cells Targeting Melanoma

This trial is testing CAR-T cell therapy — immune cells engineered to target two proteins (NG2 and DLL3) found on melanoma and other cancers — in patients whose cancer has progressed after standard first-line treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have a confirmed tumor that expresses NG2 and/or DLL3 proteins (tested by biopsy) - Your cancer is non-resectable, metastatic, progressive, or recurrent - You have already received and progressed on standard first-line treatment - You weigh at least 40 kg and have a life expectancy of at least 8 weeks - Any serious side effects from prior treatments have resolved to grade 2 or lower **You may NOT be eligible if...** - Your tumor does not express NG2 or DLL3 - You have not yet received first-line therapy - You have recently had a stem cell or bone marrow transplant - Your weight is below 40 kg or life expectancy is under 8 weeks Talk to your doctor to see if this trial is right for you.